New study suggests combination of statin and omega-3 fatty acid may provide cardioprotective effects

New findings from an in vitro study, led by researchers at Brigham and Women's Hospital (BWH), show that the combination of statins and eicosapentaenoic acid (EPA), an omega-3 fatty acid, may potentially reduce cardiovascular risk. This research is being presented May 1 at a peer-reviewed poster session at the National Lipid Association Scientific Sessions in Orlando, Florida.

"We know that endothelial cell dysfunction is emerging as an early and important predictor of and plays an essential role in plaque development. Treatments that provide beneficial effects on could have very important implications for a patient population at high risk for ," said R. Preston Mason, PhD, of BWH's Department of Medicine and lead author of the study. "We found that a combination of statins and EPA omega-3 fatty acid, or fish oil, had on and function."

Using human tissue, researchers analyzed whether EPA could enhance the benefits of statins on endothelial cells. Blood vessels from human umbilical vein cells were collected from healthy donors and then subjected to disease-like conditions in the laboratory using oxidized low-density lipoproteins (LDL). Using nanotechnology approaches, researchers measured the release of molecules from the endothelial cells including nitric oxide, an essential regulator of blood vessel health. The researchers found that the combination of EPA and a statin was more than 50 percent better than the statin alone in reversing endothelial damage.

Researchers conclude that there is a potent and favorable interaction between the omega-3 fatty acid, EPA, and widely used statins, and suggest that a therapeutic strategy with this combination may be beneficial patients with increased risk for CV disease.

These new results may also underscore the importance of coupling high-quality statin therapies with an omega-3 agent such as EPA in potentially reducing , in addition to treating elevated triglycerides. High circulating triglyceride levels are considered a risk factor associated with cardiovascular disease, along with HDL, LDL cholesterol and blood pressure. New strategies to help patients manage this aspect of cardiovascular risk show promise in the overall prevention and treatment of heart disease.

The researchers note that future research is needed, particularly in humans, including cardiovascular outcomes data in randomized clinical trials.

add to favorites email to friend print save as pdf

Related Stories

Are statins good for your love life?

Mar 29, 2014

Statins are associated with a significant improvement in erectile function, a fact researchers hope will encourage men who need statins to reduce their risk of heart attack to take them, according to research to be presented ...

Recommended for you

Results of RIBS IV trial reported

5 hours ago

A new clinical trial comparing the use of everolimus-eluting stents (EES) and drug-eluting balloons (DEB) in treating in-stent restenosis (ISR) from drug-eluting stents found that EES provided superior late angiographic results ...

Results of DKCRUSH-VI trial reported

5 hours ago

A new study found that fractional flow reserve (FFR)-guided provisional side branch (SB) stenting of true coronary bifurcation lesions yields similar outcomes to the current standard of care. The DKCRUSH-VI clinical trial ...

Results of IVUS-CTO trial reported at TCT 2014

6 hours ago

A new study found that intravascular ultrasound (IVUS) -guided intervention in patients with chronic total occlusion (CTO) could improve outcomes compared to a conventional angiography-guided approach during percutaneous ...

Results of OCT STEMI trial reported at TCT 2014

6 hours ago

The first randomized trial to examine serial optical coherence tomography (OCT) in primary percutaneous coronary intervention (PCI) was reported at the 26th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific ...

INR variability predicts warfarin adverse effects

11 hours ago

(HealthDay)—Unstable anticoagulation predicts warfarin adverse effects regardless of time in therapeutic range, according to a study published online Sept. 2 in Circulation: Cardiovascular Quality and Ou ...

User comments